55I LLC’s ARK Genomic Revolution ETF ARKG Stock Holding History

55I LLC’s Portfolio ARKG Stock Details ARKG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-2,716	Closed	-$251K	–	475
2021 Q2	$251K	Buy	+2,716	New	+$231K	0.01%	351

Other funds holding ARKG

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

55I LLC's ARKG Position: Q3 2021 in Review

55I LLC sold out of ARK Genomic Revolution ETF (ARKG) in Q3 2021, closing a stake of 2,716 shares — an estimated $251K sold.

55I LLC first reported a position in ARKG in Q2 2021 and held it in 1 quarter. The position peaked at $251K in Q2 2021. 468 funds tracked by Wall St. Rank hold ARKG as of Q3 2021.

55I LLC reported no remaining ARK Genomic Revolution ETF position as of Q3 2021 after selling out during the quarter.
55I LLC sold 2,716 ARK Genomic Revolution ETF shares in Q3 2021, an estimated $251K.
55I LLC first reported a position in ARK Genomic Revolution ETF in Q2 2021 and held it in 1 quarter.
55I LLC's ARK Genomic Revolution ETF position peaked at $251K in Q2 2021.
468 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q3 2021.

Based on 55I LLC's 13F filing for Q3 2021, filed 9 Nov 2021.